Brokerages Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $20.33

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has received an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $20.3333.

Several research analysts recently commented on ENTA shares. JMP Securities increased their price objective on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 12th. Jefferies Financial Group raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price target for the stock from $14.00 to $20.00 in a research note on Wednesday, October 1st. Westpark Capital boosted their price target on shares of Enanta Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, September 30th. JPMorgan Chase & Co. started coverage on shares of Enanta Pharmaceuticals in a research note on Friday, November 14th. They set an “overweight” rating and a $17.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Wednesday, October 8th.

Enanta Pharmaceuticals Trading Up 3.6%

ENTA stock opened at $14.60 on Friday. Enanta Pharmaceuticals has a 12-month low of $4.09 and a 12-month high of $15.34. The business’s 50-day moving average is $11.89 and its 200 day moving average is $9.04. The stock has a market cap of $421.36 million, a price-to-earnings ratio of -3.81 and a beta of 0.96.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($1.13) by $0.26. The business had revenue of $15.13 million for the quarter, compared to the consensus estimate of $15.60 million. Enanta Pharmaceuticals had a negative return on equity of 93.76% and a negative net margin of 125.36%. As a group, equities analysts forecast that Enanta Pharmaceuticals will post -4.65 EPS for the current fiscal year.

Insiders Place Their Bets

In other Enanta Pharmaceuticals news, insider Tara Lynn Kieffer sold 2,106 shares of the company’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $14.23, for a total value of $29,968.38. Following the completion of the sale, the insider directly owned 30,620 shares in the company, valued at $435,722.60. This represents a 6.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Yat Sun Or sold 2,390 shares of Enanta Pharmaceuticals stock in a transaction on Friday, December 5th. The stock was sold at an average price of $14.23, for a total value of $34,009.70. Following the transaction, the insider owned 371,392 shares in the company, valued at approximately $5,284,908.16. This represents a 0.64% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 11,961 shares of company stock valued at $170,149. Insiders own 13.89% of the company’s stock.

Institutional Trading of Enanta Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its position in shares of Enanta Pharmaceuticals by 5.3% during the first quarter. Goldman Sachs Group Inc. now owns 130,410 shares of the biotechnology company’s stock worth $720,000 after purchasing an additional 6,549 shares in the last quarter. Farther Finance Advisors LLC grew its stake in Enanta Pharmaceuticals by 11,558.0% during the 2nd quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company’s stock worth $44,000 after buying an additional 5,779 shares during the last quarter. CWM LLC increased its position in Enanta Pharmaceuticals by 22.1% during the second quarter. CWM LLC now owns 21,464 shares of the biotechnology company’s stock worth $162,000 after buying an additional 3,879 shares during the period. Ieq Capital LLC acquired a new position in Enanta Pharmaceuticals during the first quarter worth approximately $232,000. Finally, Bank of Montreal Can lifted its stake in Enanta Pharmaceuticals by 32.8% in the second quarter. Bank of Montreal Can now owns 33,868 shares of the biotechnology company’s stock valued at $256,000 after buying an additional 8,365 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.